Eisai Opens Multi-million Pound High Tech Global Potent Packaging Facility for New Cancer Treatment in UK
Eisai, a leading global R&D-based pharmaceutical company, has opened a new facility at its EMEA Knowledge Centre in Hatfield, UK, to handle the packaging of its investigational compound lenvatinib, for the treatment of advanced thyroid cancer. This represents a foreign direct investment of more than £8 million into the UK by the Japanese company.
Housing innovative hybrid packaging lines at the cutting edge of technology, the facility is specifically designed to cope with highly potent, difficult-to-handle compounds. The new two storey 2900 m2 facility expands the current Hatfield site by nearly 40% and reflects Eisai’s commitment to a long-term global business structure in which the UK is a key hub. The Hatfield site hosts the company’s EMEA headquarters and serves as a global supply centre of excellence for key products.
“Pharmaceuticals manufacturing is important to our economy, with more than £22 billion worth of exports in 2013 and a positive trade balance of just over £2 billion. Eisai's investment in this new facility will help grow these figures and is another vote of confidence for the UK’s world-class life sciences sector,” commented George Freeman MP, Minister for Life Sciences.
“The Government continues in its commitment to ensure that the UK life sciences sector is innovative and flexible, through new measures announced last week such as the Innovative Medicines and MedTech Review and the latest round of Biomedical Catalyst funding. We are committed to finding new ways to improve the lives of patients and give companies the confidence to invest and create jobs in the UK,” he added.
Eisai has invested more than £150 million in the Hatfield site, representing the largest Japanese pharmaceutical investment in the UK to date. It is home to more than 500 employees, and has the capacity to produce up to 450 million tablets in 10 million packs each year. The new packaging facility will increase employment at the site by 10% and boost the revenues of local businesses and suppliers.
"We are extremely proud of this new development at our EMEA Knowledge Centre. The UK is an ideal location for advanced manufacturing. We are committed to the life sciences industry in this country and it will continue to play a pivotal role in our commercial growth strategy,” Haruo Naito, CEO of Eisai Co., Ltd. said.
"This new high tech facility enhances our capability as a centre of packaging excellence for our growing product range,” he added. “As we supply products to an increasing number of countries with different languages across the world, our facility needs to cope with an extremely high mix of low-volume packaging for often difficult-to-handle compounds. The new machines were tailor-made and allow for reconfiguration of every product run particular to each national market we supply. Lenvatinib will be packaged exclusively at Hatfield and eventually export to almost 200 countries, contributing positively to the UK balance of trade.”
Lenvatinib, discovered and developed by Eisai, was granted orphan drug designation for follicular and papillary thyroid cancer by the European Commission in 2013. Regulatory submissions have been made in the EU, US and Japan. The European Medicines Agency has accepted a request for accelerated approval of lenvatinib for advanced thyroid cancer. Lenvatinib also has the potential to treat other cancers.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance